Alyssa Botelho
Datos Biográficos
| ID | 6080663 |
|---|---|
| NOMBRE | Alyssa Botelho |
| NOMBRES | Alyssa |
| APELLIDO | Botelho |
| FIRMA | BOTELHO A |
| AFILIACIONES | A. Jay Holmgren is with the Harvard Business School, Harvard University, Boston, MA. Alyssa Botelho is with the Medical Scientist Training Program, Harvard Medical School, Boston, MA, and the Department of the History of Science, Harvard University, Cambridge, MA. Allan M. Brandt is with the Department of Global Health and Social Medicine, Harvard Medical School, Boston, and the Department of the History of Science, Harvard University, Cambridge. |
| VERIFICADO | No |
| TOTAL DE OBRAS | 2 |
| TOTAL DE CITAS | 3 |
| TOTAL COMO AUTOR | 2 |
| TOTAL COMO EDITOR | 0 |
| PRIMER AÑO DE PUBLICACIÓN | 2019 |
| AÑO MÁS RECIENTE DE PUBLICACIÓN | 2020 |
| ÍNDICE H | 1 |
A History of Prescription Drug Monitoring Programs in the United States
Prescription drug monitoring programs (PDMPs) have become a widely embraced policy to address the US opioid crisis. Despite mixed scientific evidence on their effectiveness at improving health and reducing overdose deaths, 49 states and Washington, DC have adopted PDMPs, and they have received strong bipartisan legislative support. This article explores the history of PDMPs, tracking their evolution from paper-based administrative databases in th…
The Insights of Radical Science in the CRISPR Gene-Editing Era
In the wake of controversy over human embryonic gene-editing with CRISPR/Cas9 technology, scientists and commentators have looked repeatedly to the 1975 Asilomar Conference on Recombinant DNA (rDNA) as a model for adjudicating gene-editing today. STS scholars, however, have long critiqued Asilomar as a case of insular scientific self-regulation. Looking beyond Asilomar, other histories from the early biotech years offer fresh insights for those w…
A History of Prescription Drug Monitoring Programs in the United States
Prescription drug monitoring programs (PDMPs) have become a widely embraced policy to address the US opioid crisis. Despite mixed scientific evidence on their effectiveness at improving health and reducing overdose deaths, 49 states and Washington, DC have adopted PDMPs, and they have received strong bipartisan legislative support. This article explores the history of PDMPs, tracking their evolution from paper-based administrative databases in th…
The Insights of Radical Science in the CRISPR Gene-Editing Era
In the wake of controversy over human embryonic gene-editing with CRISPR/Cas9 technology, scientists and commentators have looked repeatedly to the 1975 Asilomar Conference on Recombinant DNA (rDNA) as a model for adjudicating gene-editing today. STS scholars, however, have long critiqued Asilomar as a case of insular scientific self-regulation. Looking beyond Asilomar, other histories from the early biotech years offer fresh insights for those w…
The Insights of Radical Science in the CRISPR Gene-Editing Era
In the wake of controversy over human embryonic gene-editing with CRISPR/Cas9 technology, scientists and commentators have looked repeatedly to the 1975 Asilomar Conference on Recombinant DNA (rDNA) as a model for adjudicating gene-editing today. STS scholars, however, have long critiqued Asilomar as a case of insular scientific self-regulation. Looking beyond Asilomar, other histories from the early biotech years offer fresh insights for those w…
A History of Prescription Drug Monitoring Programs in the United States
Prescription drug monitoring programs (PDMPs) have become a widely embraced policy to address the US opioid crisis. Despite mixed scientific evidence on their effectiveness at improving health and reducing overdose deaths, 49 states and Washington, DC have adopted PDMPs, and they have received strong bipartisan legislative support. This article explores the history of PDMPs, tracking their evolution from paper-based administrative databases in th…
Law (2 obras) · Political science (2 obras) · Appeal (1 obras) · Biology (1 obras) · Biomedical Ethics and Regulation (1 obras) · Cas9 (1 obras) · Commercialization (1 obras) · Corporate governance (1 obras) · CRISPR (1 obras) · CRISPR and Genetic Engineering (1 obras)